OX40

OX40 Molekülinformation

Englischer Name	Tumor necrosis factor receptor superfamily member 4	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	27	Target-Alias	ATC35 Antigen，OX40 Antigen，ACT35，IMD16，OX40，Receptors， OX40，ACT35 antigen，TNFRSF4，CD134，TNF Receptor Superfamily Member 4，TAX Transcriptionally-Activated Glycoprotein 1 Receptor，CD134 Antigen，TXGP1L，Tumor Necrosis Factor Receptor Superfamily， Member 4，Lymphoid Activation Antigene ACT35，OX40 Homologue，Tumor necrosis factor receptor superfamily member 4，Tax-Transcriptionally Activated Glycoprotein 1 Receptor，OX40 Cell Surface Antigen，OX40L receptor
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Tumor necrosis factor receptor superfamily member 4
Target-Alias	ATC35 Antigen，OX40 Antigen，ACT35，IMD16，OX40，Receptors， OX40，ACT35 antigen，TNFRSF4，CD134，TNF Receptor Superfamily Member 4，TAX Transcriptionally-Activated Glycoprotein 1 Receptor，CD134 Antigen，TXGP1L，Tumor Necrosis Factor Receptor Superfamily， Member 4，Lymphoid Activation Antigene ACT35，OX40 Homologue，Tumor necrosis factor receptor superfamily member 4，Tax-Transcriptionally Activated Glycoprotein 1 Receptor，OX40 Cell Surface Antigen，OX40L receptor
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	27
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

OX40 Produktliste

Attribut
Protein (15)Cell (2)Kits (2)
Produktbibliothek
Online (19)
Spezies
Human (9)Mouse (3)Cynomolgus / Rhesus macaque (3)Rat (2)Rabbit (1)Canine (1)
Etikett
Fc Tag (5)His Tag (5)Fc Tag & Avi Tag (1)His Tag & Avi Tag (3)Mouse IgG Fc Tag (1)- (4)
Marker
Unconjugated (11)Biotin-labeled (4)- (4)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT OX0-H5224	Human	HEK293	Human OX40 / TNFRSF4 / CD134 Protein, His Tag (MALS verified)	In den Warenkorb legen
HOT OX0-H5252	Human	HEK293	Human OX40 / TNFRSF4 / CD134 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)	In den Warenkorb legen
HOT OX0-H5255	Human	HEK293	Human OX40 / TNFRSF4 / CD134 Protein, Fc Tag, low endotoxin (MALS verified)	In den Warenkorb legen
HOT TN4-H82E4	Human	HEK293	Biotinylated Human OX40 / TNFRSF4 / CD134 Protein, Avitag™,His Tag (MALS verified) (recommended for biopanning)	In den Warenkorb legen
HOT OX0-C82E9	Cynomolgus / Rhesus macaque	HEK293	Biotinylated Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
CHEK-ATF135	Human	HEK293	Human OX40 (Luc) HEK293 Reporter Cell	In den Warenkorb legen
CHEK-ATP053	Human	HEK293	HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line	In den Warenkorb legen
EP-162	Human	-	OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit	In den Warenkorb legen
FRT-P014	Human	-	Human OX40 / OX40 Ligand Inhibitor Screening Kit (TR-FRET)	In den Warenkorb legen
OX0-H82F7	Human	HEK293	Biotinylated Human OX40 Protein, Fc,Avitag™ (MALS verified)	In den Warenkorb legen

Gesamtmenge19

OX40 Molekülhintergrund

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

OX40 Molekülalias

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

Antikörperprojekt-Handelsplattform

Projektname	Projektphase	Molekültyp	Molekülquelle	Krankheitsgebiet	Indikationen
OX40 mAb - 01	Lead	Monoclonal	Humanized Mouse	AutoImmunity	Autoimmune disease

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Rocatinlimab	KHK-4083; AMG-451	Phase 3 Clinical	Amgen Inc, Kyowa Hakko Kirin Co Ltd	Abdominal Pain; Asthma; Autoimmune Diseases; Colitis; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Digestive System Diseases; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Intestinal Diseases; Prurigo Nodularis	Details
Ivuxolimab	PF-8600; PF-04518600	Phase 3 Clinical	Pfizer Inc	Bone metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Triple Negative Breast Neoplasms	Details
INBRX-106	INBRX-106; ES-102; ES102	Phase 3 Clinical	Inhibrx	Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Head and Neck Neoplasms; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms	Details
GSK3174998	GSK3174998; GSK 3174998; GSK-3174998	Phase 2 Clinical	Glaxosmithkline Plc	Multiple Myeloma; Neoplasms	Details
Telazorlimab	GBR-830; ISB-830	Phase 2 Clinical	Glenmark Pharmaceuticals Ltd	Dermatitis, Atopic	Details
Tavolimab	MEDI-0562	Phase 2 Clinical	Medimmune	Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms, Squamous Cell; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
HX-111	HX-111; HX111	Phase 2 Clinical	Hanx Biopharmaceuticals (Wuhan) Co Ltd	Hematologic Neoplasms; Lymphoma; Solid tumours	Details
CS-01	CS01; CS-01	Phase 2 Clinical	Zhongshan Constimulus Bio Co Ltd	Solid tumours	Details
Brivekimig	SAR-442970; SAR442970	Phase 2 Clinical	Sanofi	Colitis, Ulcerative; Crohn Disease; Diabetes Mellitus, Type 1; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hidradenitis Suppurativa; Inflammation; Nephrosis	Details
IMG-007	IMG-007	Phase 2 Clinical		Alopecia Areata; Dermatitis, Atopic; Eczema	Details
BAT-6026	BAT-6026	Phase 2 Clinical	Bio-Thera Solutions Ltd, Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd	Autoimmune Diseases; Dermatitis, Atopic; Solid tumours	Details
Gimistotug	BGB-A445	Phase 2 Clinical	BeOne Medicines Ltd	Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Melanoma; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
Recombinant human anti-OX40 monoclonal antibody (Livzon Group)		Phase 1 Clinical	Livzon Pharmaceutical Group Inc	Neoplasms	Details
SL-279252	TAK-252; SL-279252	Phase 1 Clinical	Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd	Adenocarcinoma; Astrocytoma; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms	Details
FS-120	FS-120	Phase 1 Clinical	F-Star	Neoplasm Metastasis; Neoplasms	Details
Cudarolimab	IBI-101	Phase 1 Clinical		Neoplasms; Solid tumours	Details
Revdofilimab	ABBV-368; PR-1628103	Phase 1 Clinical	Abbvie Inc	Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
SHR-1806	SHR-1806	Phase 1 Clinical	Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd	Neoplasms	Details
BMS-986178	BMS-986178	Phase 1 Clinical	Bristol-Myers Squibb Company	Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms; Solid tumours; Waldenstrom Macroglobulinemia	Details
EMB-09	EMB-09	Phase 1 Clinical	Shanghai Epimab Biotherapeutics, Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hepatitis B, Chronic; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms	Details
PeptiCRAd-1	Valo-D102; PeptiCRAd-1	Phase 1 Clinical	Valor Biotherapeutics	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma, Myxoid; Neoplasms; Osteosarcoma; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Triple Negative Breast Neoplasms	Details
Cenzestotug	YH-002	Phase 1 Clinical		Solid tumours	Details
SAR-446422	SAR446422; SAR-446422	Phase 1 Clinical	Sanofi	Autoimmune Diseases	Details
STAR-0310	ISB-830-X8; STAR-0310; STR-310	Phase 1 Clinical	Ichnos Sciences Inc	Dermatitis, Atopic	Details
HFB-3010	HFB-301001; HFB-3010	Phase 1 Clinical	HiFiBiO Therapeutics	Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Melanoma; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms	Details
HLX-51	HLX-51	Phase 1 Clinical		Lymphoma; Solid tumours	Details
MEDI-6469	MEDI-6469; AGX-051	Phase 1 Clinical	AgonOx Inc, Astrazeneca Plc, Providence Cancer Center, Providence Health & Services	Colorectal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Neoplasms; Prostatic Neoplasms; Solid tumours	Details